Tech Company Financing Transactions
BlackThorn Therapeutics Funding Round
On 1/6/2017, BlackThorn Therapeutics received $14 million in Series A funding from Biomatics Capital Partners and GV.
Transaction Overview
Company Name
Announced On
1/6/2017
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series A
Investors
GV (Blake Byers)
Proceeds Purpose
BlackThorn plans to use the additional funding to progress its lead clinical-stage asset, BTRX-246040, through Phase 2 clinical development, as well as to conduct additional exploratory pilot studies in targeted indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
780 Brannan St.
San Francisco, CA 94103
USA
San Francisco, CA 94103
USA
Phone
Undisclosed
Website
Email Address
Overview
BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Paul Berns
Chief Medical Officer
Jane Tiller
Chief Operating Officer
William Martin
VP - Regulatory Affairs
Laura Hansen
Browse more venture capital transactions:
Prev: 1/6/2017: Centrexion Therapeutics venture capital transaction
Next: 1/6/2017: Ninthdecimal venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs